Results 71 to 80 of about 4,245 (206)

Calcium Channel Blockers Inhibit Pancreatic Neuroendocrine Neoplasms Progression via Cav1.2‐Epigenetic Circuit

Advanced Science, Volume 13, Issue 20, 9 April 2026.
Our study reveals a novel mechanism of a positive regulatory circuit between Cav1.2 and H3K27ac for pancreatic neuroendocrine neoplasms (pNENs) progression. Cav1.2 is identified as a crucial target for promoting disease progression and correlates with malignant behaviors, which are remarkably inhibited by the administration of calcium channel blockers (
Yangyinhui Yu, Qiongcong Xu, Jinzhao Xie, Mingjian Ma, Xitai Huang, Yinhao Shi, Jiawei Zhou, Enliang Zhu, Ziyi Zhao, Ning Zhang, Zhide Liu, Jingyuan Ye, Xiaoyu Yin   +12 more
wiley   +1 more source

Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy

, 2011
Peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC or 177Lu-DOTATATE has demonstrated its efficacy in the treatment of neuroendocrine- and somatostatin-receptor expressing tumours .
Andrea Piccin, Irene Pusceddu, Piccin, Andrea, Sergio Cortelazzo, Chiara Maria Grana, Giovanni Negri, Paganelli, Giovanni, Giovanni Paganelli, Cortelazzo, Sergio, Negri, Giovanni, Grana, Chiara Maria, Pusceddu, Irene   +11 more
core   +1 more source

Improving the quality of care delivery during Peptide Receptor Radionuclide Therapy (PRRT) for patients with Neuroendocrine Neoplasms (NENs): Development and implementation of personalised patient planners (PPS) to streamline complex multidisciplinary care

, 2020
Peptide Receptor Radionuclide Therapy (PRRT) is a complex treatment modality for patients and their carers to navigate alone. As PRRT is a tertiary/quaternary service, patients are often referred from smaller institutions with potential for confusion due
Corsini, Nadia, Chan, Bryan, Mercurio, Jessica, Eckert, Marion, Cummins, Meredith, Altus, Liesl, Cehic, Gabrielle   +6 more
core   +1 more source

Direct estimation of activity concentration in regional voxels with application to 177Lu peptide receptor radionuclide therapy

Medical Physics, Volume 53, Issue 4, April 2026.
Abstract Background Quantitative SPECT in radionuclide‐therapy is limited by partial‐volume effects (PVEs). The implementation of regional voxels (r.v.), estimating mean activity concentrations in regions directly from projections, offers a promising alternative for the geometry‐specification to reduce PVEs.
Johan Gustafsson, Erik Larsson, Katarina Sjögreen Gleisner   +2 more
wiley   +1 more source

A Rapid and Safe Infusion Protocol for Lu-177 Peptide Receptor Radionuclide Therapy

, 2021
Peptide receptor radionuclide therapy (PRRT) with 177Lu-labeled somatostatin analogs in patients with somatostatin receptor-expressing tumors is often performed using administration protocols prescribing a 30-min infusion time. The most often used method
Barentsz, Maarten W, de Keizer, Bart, Lam, Marnix G E H, Ebbers, Sander C, Braat, Arthur J A T, Krijger, Gerard C   +5 more
core  

Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies [PDF]

, 2015
Background: Successful treatments of patients with somatostatin receptor (SSTR)-overexpressing neuroendocrine tumours (NET) comprise somatostatin-analogue lutetium-177-labelled octreotate (177Lu-TATE) treatment, also referred to as peptide receptor ...
Melis, M.L. (Marleen), Groen, H.C. (Harald), Bison, S.M. (Sander), Jong, M. (Marion) de, Veenland, J.F. (Jifke), Bernsen, M.R. (Monique), Haeck, J.C. (Joost), Koelewijn, S. (Stuart), Bol, K. (Karin)   +8 more
core   +3 more sources

Enhancing Diagnostic Pathways for Bronchopulmonary Neuroendocrine Tumors: Assessment of the South Wales Neuroendocrine Tumor Service Transformation

Thoracic Cancer, Volume 17, Issue 8, April 2026.
Implementation of a dedicated neuroendocrine cancer service in South Wales significantly shortened diagnostic and treatment timelines for bronchopulmonary NETs, demonstrating the benefits of coordinated specialist input. ABSTRACT Background Bronchopulmonary neuroendocrine tumors (bpNETs) are uncommon lung neoplasms posing significant diagnostic and ...
Arouba Imtiaz, Oliver Burbidge, Mat Jones, Robin Ghosal, Janardhan Navaratnam, Craig Dyer, Helen E. Davies, Mohid S. Khan   +7 more
wiley   +1 more source

Peptide Receptor Radionuclide Therapy (PRRT) of Neuroendocrine Tumors: Current State and Future Perspectives

International Journal of Endocrine Oncology, 2015
The heterogeneous nature of neuroendocrine tumors, their indolent course and lack of therapeutic options for the management of advanced cases – together form the Achilles heel for oncologists. Somatostatin receptor-specific imaging with Ga-68 labeled peptides has provided an opportunity for management of advanced cancers with their therapeutic ...
Richard P Baum, Ameya D Puranik, Harshad R Kulkarni   +2 more
openaire   +1 more source

Five Advances in the Last 50 Years That Have Impacted Endocrine Surgery

World Journal of Surgery, EarlyView.
Matilda Anneback, Priya H. Dedhia, Aimee Di Marco, Els Nieveen van Dijkum, Julie A. Miller, Janice L. Pasieka   +5 more
wiley   +1 more source

Endoscopic Ultrasound for the Management of Pancreatic Neuroendocrine Tumors: Diagnosis, Treatment, and Future Perspectives

Journal of Gastroenterology and Hepatology, Volume 41, Issue 4, Page 1173-1190, April 2026.
ABSTRACT Pancreatic neuroendocrine tumors (PanNETs) are increasingly diagnosed, reflecting greater clinical awareness, improved imaging, and revised classification. This review summarizes evidence on epidemiology, diagnostic workup, and endoscopic ultrasound (EUS)–guided management of PanNETs, encompassing diagnostic evaluation, tissue acquisition, and
Angelo Bruni, David Meacci, Roberto Falbo, Marco Fichera, Francesco Poggioli, Riccardo Casadei, Claudio Ricci, Leonardo Henry Eusebi   +7 more
wiley   +1 more source